Low glucose enhanced metformin’s inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Andersen DK. Diabetes and cancer: placing the association in perspective. Curr Opin Endocrinol Diabetes Obes. 2013;20(2):81–86.
   PubMedGoogle Scholar
• Szablewski L. Diabetes mellitus: influences on cancer risk. Diabetes Metab Res Rev. 2014;30(7):543–553.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–748.
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Chang JS. Environmental risk factors of pancreatic cancer. J Clin Med. 2019;8:9.
   Web of Science ®Google Scholar
• Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981–987.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Li D, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. Ann Oncol. 2014;25(10):2065–2072.
   PubMed Web of Science ®Google Scholar
• Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. Bmj. 2015 jan 02;349(3):g7371–g7371. .
   Google Scholar
• Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482–488.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 2012;107(4):620–626.
   PubMed Web of Science ®Google Scholar
• Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–966.
   PubMed Web of Science ®Google Scholar
• Andrzejewski S, Siegel PM, St-Pierre J. Metabolic profiles associated with metformin efficacy in cancer. Front Endocrinol (Lausanne). 2018;9:372.
   PubMed Web of Science ®Google Scholar
• Bridges HR, Jones AJ, Pollak MN, et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014;462(3):475–487.
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174.
   PubMed Web of Science ®Google Scholar
• Sylvia Andrzejewski S-PG, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014;2(1):12.
   PubMedGoogle Scholar
• Song IS, Han J, Lee HK. Metformin as an anticancer drug: A Commentary on the metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. J Diabetes Investig. 2015;6(5):516–518.
   PubMed Web of Science ®Google Scholar
• Wahdan-Alaswad RS, Edgerton SM, Salem HS, et al. Metformin targets glucose metabolism in triple negative breast cancer. J Oncol Transl Res. 2018;4:1.
   Google Scholar
• Tang D, Xu L, Zhang M, et al. Metformin facilitates BG45induced apoptosis via an antiWarburg effect in cholangiocarcinoma cells. Oncol Rep. 2018;39(4):1957–1965.
   PubMed Web of Science ®Google Scholar
• Faubert B, Boily G, Izreig S, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17(1):113–124.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
   PubMed Web of Science ®Google Scholar
• Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66(18):8927–8930.
   PubMed Web of Science ®Google Scholar
• Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211–218.
   PubMed Web of Science ®Google Scholar
• Cassim S, Raymond VA, Lacoste B, et al. Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma. Oncotarget. 2018;9(42):26868–26883.
   PubMedGoogle Scholar
• Cassim S, Pouyssegur J. Tumor microenvironment: a metabolic player that shapes the immune response. Int J Mol Sci. 2019;21(1):1.
   Web of Science ®Google Scholar
• Cassim S, Raymond VA, Dehbidi-Assadzadeh L, et al. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle. 2018;17(7):903–916.
   PubMed Web of Science ®Google Scholar
• Ždralević M, Brand A, Di IL, et al. Double genetic disruption of lactate dehydrogenases A and B is required to ablate the “Warburg effect” restricting tumor growth to oxidative metabolism. J Biol Chem. 2018;293(41):15947–15961.
   PubMed Web of Science ®Google Scholar
• Ma L, Wei J, Wan J, et al. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res. 2019;38(1):77.
   PubMedGoogle Scholar
• Litchfield LM, Mukherjee A, Eckert MA, et al. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015;6(27):23548–23560.
   PubMedGoogle Scholar
• Bikas A, Jensen K, Patel A, et al. Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. Endocr Relat Cancer. 2015;22(6):919–932.
   PubMed Web of Science ®Google Scholar
• Zordoky BN, Bark D, Soltys CL, et al. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta. 2014;1840(6):1943–1957.
   PubMed Web of Science ®Google Scholar
• Wahdan-Alaswad R, Fan Z, Edgerton SM, et al. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013;12(24):3759–3769.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Calin GA, Lopez-Berestein G, et al. miRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov. 2016;6(3):235–246.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–159.
   PubMed Web of Science ®Google Scholar
• Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13(4):239–250.
   PubMed Web of Science ®Google Scholar
• Sun FB, Lin Y, Li SJ, et al. MiR-210 knockdown promotes the development of pancreatic cancer via upregulating E2F3 expression. Eur Rev Med Pharmacol Sci. 2018;22(24):8640–8648.
   PubMed Web of Science ®Google Scholar
• Yu Q, Xu C, Yuan W, et al. Evaluation of plasma MicroRNAs as diagnostic and prognostic biomarkers in pancreatic adenocarcinoma: miR-196a and miR-210 could be negative and positive prognostic markers, respectively. Biomed Res Int. 2017;2017:6495867.
   PubMed Web of Science ®Google Scholar
• Wheaton WW, Weinberg SE, Hamanaka RB, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242.
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576–3586.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–10812.
   PubMed Web of Science ®Google Scholar
• Lee MS, Hsu CC, Wahlqvist ML, et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
   PubMed Web of Science ®Google Scholar
• Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res. 2016;22(5):1076–1085.
   PubMed Web of Science ®Google Scholar
• Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16(7):839–847.
   PubMed Web of Science ®Google Scholar
• Li X, Li T, Liu Z, et al. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep. 2017;7(1):5825.
   PubMed Web of Science ®Google Scholar
• Wan G, Sun X, Li F, et al. Survival benefit of metformin adjuvant treatment for pancreatic cancer patients: a systematic review and meta-analysis. Cell Physiol Biochem. 2018;49(3):I.
   Google Scholar
• He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab. 2015;21(2):159–162.
   PubMed Web of Science ®Google Scholar
• Okar DA, Manzano A, Navarro-Sabate A, et al. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci. 2001;26(1):30–35.
   PubMed Web of Science ®Google Scholar
• Yalcin A, Telang S, Clem B, et al. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol. 2009;86(3):174–179.
   PubMed Web of Science ®Google Scholar
• Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers (Basel). 2019;11:6.
   Web of Science ®Google Scholar
• Granchi C, Bertini S, Macchia M, et al. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem. 2010;17(7):672–697.
   PubMed Web of Science ®Google Scholar
• Valvona CJ, Fillmore HL, Nunn PB, et al. The regulation and function of lactate dehydrogenase a: therapeutic potential in brain tumor. Brain Pathol. 2016;26(1):3–17.
   PubMed Web of Science ®Google Scholar